4 展望
对于AR，还存在很多未知因素，其复杂性和群体特征性是并存的，需进一步深入研究。在研究AR及临床防治AR时，应在考虑其复杂性的基础上，兼顾群体差别性，区别地辨证地对待这种现象，针对不同的群体制定不同的研究方案，为不同的个体制定更有效的治疗策略，使个体化治疗得到更高层次的体现。比如，我们可根据挟杂危险因素的不同来划分不同的群体，通过研究这些不同群体中AR产生的机理，相应地揭示其可能的群体特征。目前，关于AR的研究还不够全面，不够系统，也存在很多争议，结合中医中药，针对不同的群体进行AR的产生机理及防治方面的研究是一条值得探索之路。
【参考文献】
1 Sztriha LK， Sas K， Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci. 2005; （229-230）: 163-169.
2 Weber ZZ， Zimmermann KC， Meyer-Kirchrath J， et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999; 353: 900.
3 Weber AA， Przytulski B， Schumacher M， et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients under-going coronary artery bypass grafting. Br J Haematol. 2002; 117（2）: 424-426.
4 Rocca B， Secchiero P， Ciabattoni G， et al. Cyclooxyge-nase-2 expression is induced during human megakaryo-poiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002; 99: 7634-7639.
5 Kimmel SE， Berlin JA， Reilly M， et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142（3）: 157-164.
6 Johnsen SP， Larsson H， Tarone RE， et al. Risk of hospitalization for myocardial infarction among users of rofecoxib， celecoxib， and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005; 165（9）: 978-984.
7 Nurtjahja-Tjendraputra E， Ammit AJ， Roufogalis BD， et al. Effective anti-platelet and COX-1 enzyme inhibi-tors from pungent constituents of ginger. Thromb Res. 2003; 111（4-5）: 259-265.
8 Catella-Lawson F， Reilly MP， Kapoor SC， et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345（25）: 1809-1817.
9 Cryer B， Berlin RG， Cooper SA， et al. Double-blind， randomized， parallel， placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther. 2005; 27（2）: 185-191.
10 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs. 2004; 4（3）: 151-158.
11 Helgason CM， Tortorice KL， Winkler SR， et al. Aspi-rin response and failure in cerebral infarction. Stroke. 1993; 24（3）: 345-350.
12 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death， myocardial infarction， and stroke in high risk patients. BMJ. 2002; 324（7329）: 71-86.
13 Cox D， Maree AO， Dooley M， et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin inhealthy volunteers. Stroke. 2006; 37（8）: 2153-2158
14 Macchi L， Christiaens L， Brabant S， et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107（1-2）: 45-49.